BioGaia’s probiotic to be launched in China
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia Protectis tabs in China. The product will be co-branded under BioGaia and Abbott brand. Launch of the product is planned to 2018.
BioGaia primarily focus on pediatrics, gut health and oral health and the probiotic products are available in around 90 countries.
”We have a strong focus on growing our Asian business and I am very pleased that yet another of BioGaia’s products will be available in China. Based on the positive experience we already have in collaborating with Abbott in Latin America and Thailand, I look forward to a successful launch of BioGaia Protectis tabs with Abbott in China as well”, says Axel Sjöblad, Managing Director, BioGaia.
Latest press releases from BioGaia
2018-01-11 BioGaia Protectis with vitamin D soon in the Swedish market
2018-01-10 Two new meta-analyses confirm effectiveness of BioGaia’s probiotic in infant colic
2017-11-17 Lactobacillus reuteri reduced bone loss in older women
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 90 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com